Tags

Type your tag names separated by a space and hit enter

A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria.
Bull World Health Organ. 1985; 63(2):339-43.BW

Abstract

Fansimef is a combination of 250 mg of mefloquine, 500 mg of sulfadoxine, and 25 mg of pyrimethamine per tablet. A total of 150 adult male Zambian patients who had symptomatic Plasmodium falciparum parasitaemia were treated in a double-blind randomized fashion with either one, two or three tablets of Fansimef. All patients in the three treatment groups showed an S-type response. The rates of clearance of parasitaemia and fever were similar in all treatment groups. Tolerance was good at all dose levels. The main side-effects were abdominal discomfort, weakness and lassitude, dizziness, and pruritus, but these were mild, transient and required no specific treatment. Vomiting occurred only in 4% of patients given the highest dose of three tablets. The results of various haematological and biochemical investigations and urinalysis were not adversely altered by the administration of Fansimef.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3893778

Citation

Ekue, J M., et al. "A Double-blind Clinical Trial of a Combination of Mefloquine, Sulfadoxine and Pyrimethamine in Symptomatic Falciparum Malaria." Bulletin of the World Health Organization, vol. 63, no. 2, 1985, pp. 339-43.
Ekue JM, Simooya OO, Sheth UK, et al. A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria. Bull World Health Organ. 1985;63(2):339-43.
Ekue, J. M., Simooya, O. O., Sheth, U. K., Wernsdorfer, W. H., & Njelesani, E. K. (1985). A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria. Bulletin of the World Health Organization, 63(2), 339-43.
Ekue JM, et al. A Double-blind Clinical Trial of a Combination of Mefloquine, Sulfadoxine and Pyrimethamine in Symptomatic Falciparum Malaria. Bull World Health Organ. 1985;63(2):339-43. PubMed PMID: 3893778.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria. AU - Ekue,J M, AU - Simooya,O O, AU - Sheth,U K, AU - Wernsdorfer,W H, AU - Njelesani,E K, PY - 1985/1/1/pubmed PY - 1985/1/1/medline PY - 1985/1/1/entrez SP - 339 EP - 43 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 63 IS - 2 N2 - Fansimef is a combination of 250 mg of mefloquine, 500 mg of sulfadoxine, and 25 mg of pyrimethamine per tablet. A total of 150 adult male Zambian patients who had symptomatic Plasmodium falciparum parasitaemia were treated in a double-blind randomized fashion with either one, two or three tablets of Fansimef. All patients in the three treatment groups showed an S-type response. The rates of clearance of parasitaemia and fever were similar in all treatment groups. Tolerance was good at all dose levels. The main side-effects were abdominal discomfort, weakness and lassitude, dizziness, and pruritus, but these were mild, transient and required no specific treatment. Vomiting occurred only in 4% of patients given the highest dose of three tablets. The results of various haematological and biochemical investigations and urinalysis were not adversely altered by the administration of Fansimef. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/3893778/A_double_blind_clinical_trial_of_a_combination_of_mefloquine_sulfadoxine_and_pyrimethamine_in_symptomatic_falciparum_malaria_ DB - PRIME DP - Unbound Medicine ER -